Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05576519

Enrollment

Registered

2022-10-12

Start date

2017-06-01

Completion date

2022-12-30

Last updated

2022-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Carcinoma

Keywords

Ovarian carcinoma, CSCs, EpCAM

Brief summary

Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa type I transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small intracellular domain of 26 amino acids. Recent insights revealed that it is involved in promoting cancer cell proliferation, migration, and invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently been identified as a marker for CSCs.

Detailed description

Ovarian carcinoma is one of most frequent cancer in women worldwide. Epithelial ovarian carcinoma is a group of neoplasms with different histologic pictures. Serous carcinoma is the most common type. Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa type I transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small intracellular domain of 26 amino acids. It is abundantly expressed by the majority of human epithelial carcinomas, including colorectal, breast, lung, prostate, ovarian, and endometrial cancers. it is overexpressed in various neoplasms. Recent insights revealed that it is involved in promoting cancer cell proliferation, migration, and invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently been identified as a marker for CSCs.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Inclusion criteria

* Patients with epithelial ovarian carcinoma and underwent surgery

Exclusion criteria

* \- Cases received pre-operative chemotherapy or radiotherapy. * Cases with insufficient clinical data.

Design outcomes

Primary

Measure	Time frame	Description
evaluate EpCAM expression in ovarian carcinoma	1 month	IHC

Countries

Egypt

Contacts

Primary ContactNagwa Ahmed, Lecture

nagwa.sadek@med.sohag.edu.eg01017415996

Outcome results